



Treatment Strategies and Emerging Biomarkers in High-Risk Early-Stage Melanoma

Guest Editors:

Dr. Yvonne M. Saenger

Albert Einstein College of
Medicine, Montefiore Medical
Center, New York, NY 10461, USA

Prof. Dr. Larisa J. Geskin

Department of Dermatology,
Columbia University, New York,
NY 10032, USA

Deadline for manuscript
submissions:
closed (20 January 2024)

Message from the Guest Editors

Dear Colleagues,

Melanoma remains an aggressive disease. Although patients with melanoma are most frequently diagnosed with early stage disease, they are at high risk for recurrence and subsequent death even after surgical resection, the current standard of care. Thus, increased awareness and research efforts for the management of these early-stage melanoma patients are urgently needed.

For this Special Issue, we are pleased to invite you to contribute original research articles or reviews regarding the molecular landscape of stage II–III melanoma and potential targets for treatment. We also welcome research, including basic, translational, and clinical studies, on novel approaches for the characterization and management of this subset of melanoma patients. Submissions may also recount the history of early-stage melanoma and the evolution of clinical data specific to this group.

This Special Issue aims to provide insight on the prognostic and clinical limitations that exist with traditional histopathologic and staging methods for early stage melanoma patients and call for approaches that may lead to better patient outcomes.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)